Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

Phase 2
Completed
Conditions
Systemic Sclerosis
First Posted Date
2001-05-07
Last Posted Date
2008-09-03
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT00016458
Locations
🇺🇸

University of Colorado Cancer Center, Denver, Colorado, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Phase 1
Completed
Conditions
Multiple Sclerosis
First Posted Date
2001-04-11
Last Posted Date
2005-06-24
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
35
Registration Number
NCT00014755
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

University of Colorado Cancer Center, Denver, Colorado, United States

and more 3 locations

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

First Posted Date
2001-02-02
Last Posted Date
2005-06-24
Lead Sponsor
Johns Hopkins University
Target Recruit Count
35
Registration Number
NCT00010400
Locations
🇺🇸

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Phase 2
Completed
Conditions
Pemphigus
First Posted Date
2001-02-02
Last Posted Date
2008-10-02
Lead Sponsor
Johns Hopkins University
Target Recruit Count
35
Registration Number
NCT00010413
Locations
🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

First Posted Date
2001-02-02
Last Posted Date
2008-09-10
Lead Sponsor
Johns Hopkins University
Target Recruit Count
32
Registration Number
NCT00010387
Locations
🇺🇸

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Permeability Factor in Focal Segmental Glomerulosclerosis

First Posted Date
2000-12-25
Last Posted Date
2016-02-10
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
15
Registration Number
NCT00007475
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

First Posted Date
2000-08-24
Last Posted Date
2017-10-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00006184
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

First Posted Date
2000-07-06
Last Posted Date
2005-06-24
Lead Sponsor
Fairview University Medical Center
Target Recruit Count
10
Registration Number
NCT00006055
Locations
🇺🇸

Fairview University Medical Center, Minneapolis, Minnesota, United States

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

First Posted Date
2000-07-06
Last Posted Date
2005-06-24
Lead Sponsor
Fairview University Medical Center
Target Recruit Count
40
Registration Number
NCT00006056
Locations
🇺🇸

Fairview University Medical Center, Minneapolis, Minnesota, United States

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

First Posted Date
2000-07-06
Last Posted Date
2009-10-15
Lead Sponsor
Fairview University Medical Center
Registration Number
NCT00006054
Locations
🇺🇸

Fairview University Medical Center, Minneapolis, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy